Skip to main content
. 2018 Dec 27;20:284. doi: 10.1186/s13075-018-1784-8

Table 1.

Characteristics of the patients with ankylosing spondylitis, overall and stratified and compared by sex

Variables All, n = 210 Men, n = 121 (57.6) Women, n = 89 (42.4) P value
Age, years 49.0 (40.0, 61.2) 49.0 (39.5, 61.0) 49.0 (41.5, 62.0) 0.48
BMI, kg/m2 25.2 (22.8, 28.4) 25.8 (23.6, 28.9) 24.0 (21.8, 27.5) 0.003
Civil state: single 58 (27.6) 34 (28.1) 24 (27.0) 0.86
in a relationship 152 (72.4) 87 (71.9) 65 (73.0) 0.87
Years in school: < 13 98 (46.9)a 62 (51.7)a 36 (40.4) 0.11
≥ 13 years 111 (53.1) 58 (48.3) 53 (59.6) 0.11
Ever smoker 105 (50.0) 65 (53.7) 40 (44.9) 0.21
VAS global fatigue, score 59.0 (27.0, 74.0) 50.0 (20.5, 68.0) 64.0 (42.5, 76.0) 0.002
Duration of symptoms, years 24.0 (13.0, 34.0)c 23.0 (13.0, 33.0)b 24.0 (12.5, 34.0)a 0.80
Duration of disease, years 12.0 (5.0, 23.0)a 12.5 (6.0, 24.0)a 11.0 (4.0, 18.5) 0.11
ESR, mm/h 11.0 (7.0, 19.0) 10.0 (5.0, 17.0) 14.0 (10.0, 22.5) 0.001
CRP, mg/L 3.0 (1.0, 7.0)a 3.0 (1.0, 7.0)a 2.0 (1.0, 7.5) 0.38
HLA-B27 positive 183 (87.1) 112 (92.6) 71 (79.8) 0.006
History of anterior uveitis 108 (51.5) 69 (57.0) 39 (43.8) 0.058
TNFi and/or csDMARD 73 (34.8) 45 (37.2) 28 (31.5) 0.39
BASMI, score 3.0 (2.0, 4.0) 3.0 (1.8, 4.3) 2.8 (2.2, 3.8) 0.34
BASFI, score 2.3 (1.0, 3.8)c 2.3 (1.0, 3.7)a 2.3 (1.0, 4.2)b 0.73
BASDAI, score 3.5 (1.7, 5.3)d 2.9 (1.5, 5.2)c 3.7 (1.9, 5.6)a 0.079
ASDAS-CRP, score 2.1 (1.4, 2.9)a 2.0 (1.3, 2.9)a 2.2 (1.5, 2.8) 0.70
BAS-G, score 2.90 (1.15, 5.45) 2.6 (1.0, 5.0) 3.5 (1.3, 5.7) 0.28
mSASSS, score 5.0 (0.0, 20.0) 8.0 (2.0, 34.0) 2.0 (0.0, 9.5) < 0.001
Syndesmophyte and/or 98 (46.7) 71 (58.7) 27 (30.3) < 0.001
≥ 3 intervertebral bridges consecutively, cervical and/or lumbar spine 29 (13.8) 29 (24) 0 < 0.001
PF, score 80.0 (65.0, 90.0) 80.0 (69.4, 90.0) 75.0 (60.6, 90.0) 0.023
74.4 ± 21.4 76.7 ± 21.5 71.2 ± 21.0
RP, score 75.0 (25.0, 100.0) 75.0 (25.0, 100.0) 75.0 (0.0, 100.0) 0.12
59.3 ± 41.1 63.1 ± 40.3 54.2 ± 41.8
BP, score 51.0 (41.0, 64.0) 51.0 (41.0, 72.0) 51.0 (41.0, 62.0) 0.19
54.1 ± 21.9 55.8 ± 22.8 51.7 ± 20.4
GH, score 62.0 (40.0, 77.0) 62.0 (40.0, 77.0) 60.0 (40.0, 76.0) 0.78
57.1 ± 22.8 56.6 ± 23.7 57.7 ± 21.8
VT, score 50.0 (30.0, 70.0) 55.0 (30.0, 75.0) 50.0 (30.0, 65.0) 0.010
50.6 ± 23.6 54.3 ± 24.1 45.5 ± 22.0
SF, score 75.0 (65.2, 100.0) 87.5 (62.5, 100.0) 75.0 (62.5, 100.0) 0.10
75.8 ± 25.0 77.7 ± 25.6 73.3 ± 24.1
RE, score 100.0 (33.3, 100.0)b 100.0 (33.3, 100.0)a 100.0 (33.3, 100.0)a 0.16
68.8 ± 40.8b 71.9 ± 39.8a 64.4 ± 41.9a
MH, score 76.0 (63.0, 88.0) 76.0 (64.0, 88.0) 72.0 (60.0, 84.0) 0.039
71.9 ± 19.8 73.7 ± 20.7 69.5 ± 18.3
PCS, score 42.4 (34.3, 48.7)b 43.6 (35.4, 49,4)a 41.8 (32.6, 47.5)a 0.16
41.4 ± 10.0b 42.1 ± 10.0a 40.4 ± 10.2a
MCS, score 48.0 (35.6, 55.2)b 49.2 (39.9, 56.1)a 46.0 (33.4, 53.8)a 0.13
44.8 ± 12.5b 45.9 ± 12.3a 43.3 ± 12.8a

Values are median and 25th percentile (Q1) and 75th percentile (Q3), numbers of patients and percent (%) or mean ± SD. Comparisons between men and women are assessed by Mann-Whitney U-test or Chi-square test. Significant differences are in bold text

BMI body mass index, VAS visual analogue scale, ESR erythrocyte sedimentation rate, CRP C-reactive protein, TNFi TNF inhibitor, csDMARD conventional synthetic disease modifying anti-rheumatic drug, BASMI Bath Ankylosing Spondylitis Metrology Index, BASFI Bath Ankylosing Spondylitis Functional Index, BASDAI Bath Ankylosing Spondylitis Disease Activity Index, ASDAS-CRP Ankylosing Spondylitis Disease Activity Score-CRP, BAS-G Bath Ankylosing Spondylitis Patient Global, mSASSS Modified Stoke Ankylosing Spondylitis Spine Score, PF physical function, RP role physical, BP bodily pain, GH general health, VT vitality, SF social function, RE role emotional, MH mental health, PCS physical component summary, MCS mental component summary

Number of missing data values: an = 1; bn = 2;cn = 3; dn = 4